MARKET NEWS

Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial
CicloMed Expands Fosciclopirox Phase 1 Trial
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial
Vivera Pharmaceuticals Enters Agreement Clinical Study Agreement With Parexel Biotech
IONTAS & Adaptate Biotherapeutics Enter Collaboration Agreement

  FEATURED EDITORIAL

  COMPANY PROFILE

Foster Delivery Science focuses on GMP and Formulation development Hot Melt Extrusion, applying our expertise using twin screw extruders not only for traditional solubility enhancement techniques, but to create local and long term Drug Delivery Implant and film solutions.  As extrusion is a continuous process by nature, melt granulation programs are an obvious interest for lifecycle management and new drug development. Using the industry range of FDA acceptable polymers, we can create permanent and bio-absorbable implants to deliver drugs immediately or over a desired time period.  These implants can be micro implants like ophthalmic applications or macro such as intravaginal rings. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Bioiberica Launches Natural Origin Thyroid

Bioiberica Launches Natural Origin Thyroid

Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..

LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device

LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device

LEO Pharma A/S and Portal Instruments recently announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with….

Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals

Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals

Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..

Biogen Announces Positive Phase 2 Study Results

Biogen Announces Positive Phase 2 Study Results

Biogen Inc. recently announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059, a fully humanized….

OWP Pharmaceuticals Announces Second IND Approval & Patent Application for First-Ever Liquid Oral Suspension Formulation

OWP Pharmaceuticals Announces Second IND Approval & Patent Application for First-Ever Liquid Oral Suspension Formulation

OWP Pharmaceuticals, Inc. recently announced today that it has received Investigational New Drug (IND) approval from the US FDA, and has submitted for US patent protection, for the first-ever liquid formulation of….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 18 – Parenteral Contract Manufacturing
January 8 – Capsules